|
|
|
Debbie Allison, M.S.
Senior Director of Global Competitive Intelligence
Merck
Debbie Allison is Senior Director of Global Competitive Intelligence at Merck & Co., Inc. She has been with
Merck for 28 years and worked in the competitive intelligence arena for over 7 years. Debbie leads the
effort to ensure that Merck's competitive and strategic information systems and processes remain premier
within the industry. Her responsibilities also include providing competitive intelligence to the oncology
franchise. Debbie earned a Bachelor's degree in chemistry from The College of William and Mary and a
Master's degree in medicinal chemistry from The Ohio State University. Debbie joined Merck in 1979 as a
Medicinal Chemist, supporting programs focused on discovery and development of anti-inflammatory
agents. Debbie left the labs in the mid 1980s to lead a cross-divisional, international effort to put real-time
chemical structure and reaction information at the chemist's desktop through a complete transformation of
computer-based information systems. The subsequent move to the Competitive Information group was a
perfect fit for Debbie's talent in assimilating data and computer systems with user's need for strategic insight.
"My passion is to utilize scientific and business information to help establish strategic direction for Merck."
|
| |
|
Jeffrey Beeny
Senior Manager of Business Intelligence
Thermo Fisher Scientific
Jeffrey Beeny is the Senior Manager of Business Intelligence at Thermo Fisher Scientific.
From May 2006 through November 2006, he was a key member of the Fisher Scientific anti-trust team
working on the company’s $10.6 billion merger with Thermo Electron. In support of the company’s
regulatory filings, Mr. Beeny managed the business intelligence process, an essential component of
approval from the Federal Trade Commission (FTC) and European Commission (EC). He joined Fisher
Scientific in January 2006 with the responsibility for strategic, market and competitive analysis in support of
corporate initiatives and strategic decision-making.
Prior to joining Fisher Scientific, Mr. Beeny was the Principal Market Analyst, Competitive Intelligence at
EMC Corporation. At EMC, Mr. Beeny was responsible for competitive and market analysis for the company’
s corporate strategy focused on information lifecycle management. Prior to EMC, he was the Manager of
Competitive Intelligence at Genuity, where he led competitive and strategic analysis initiatives for senior
management. In the mid- to late-1990s, Mr. Beeny was a Risk Financing Analyst at Liberty Mutual and a
Scientist for The Gillette Company - Duracell. He holds a B.S. General Science in Chemistry from Purdue
University and earned an M.B.A. in Finance and Strategy from Boston College. Mr. Beeny has been a
member of the Society of Competitive Intelligence Professionals since 2000.
|
|
|
|
Francois Bernier
Manager, Strategic Research Planning
Eisai
Dr. Francois Bernier has been working for Eisai Co. Ltd in Japan since 1997. He has been actively involved
before as a neuroscientist to develop selective estrogen receptor modulators (SERMs) for various indications
and gamma-secretase modulators for Alzheimer`s Disease. Under his leadership, the teams were able to
discover two NME. Both drugs are now under clinical evaluation and promise to address important un-met
medical needs of the elderly.
In 2004, he turned his interests towards strategic planning and was involved in developing Eisai current
midterm business plan. As a manager in the Strategic Research planning department, Dr. Bernier
developed the global competitive intelligence function at Eisai and supported Eisai research expansion in
burgeoning Asian markets that include India and Singapore. Recently, he joined Eisai CEO Office and is
responsible to manage global R&D resources allocation and strategic technology investments. His job
duties takes him to various Asian countries, the US and Europe. He has been a member of SCIP since 2005
and speaks fluently French, English and Japanese.
|
| |
|
Chris Bogan
CEO
Best Practices
Chris Bogan is the Chief Executive Officer and Founder of Best Practices®, LLC, a leader in the field of
best practice performance improvement. Based in Chapel Hill, North Carolina, Best Practices®, LLC
specializes in providing pharmaceutical, biotechnology and medical device corporations throughout the
world with business intelligence, research, benchmarking studies, and consulting services. The company's
products and services provide corporations with "Access And Intelligence For Achieving World-Class
Excellence™."
Mr. Bogan received his MBA with honors from the Harvard Business School and his bachelor's degree
magna cum laude from Amherst College. He was a Nieman Fellow at Harvard University. Mr. Bogan's work
has focused on organizational excellence, blockbuster product launches, marketing excellence, sales force
effectiveness, clinical operations and best practice improvement strategies. He has written about numerous
aspects of performance excellence and continuous improvement. In recent years, he has concentrated on
ways that companies can use best practice insights to create economic value, accelerate revenue and
profit growth, and drive rapid performance improvement. He is co-author of the widely acclaimed books,
Benchmarking For Best Practices: Winning Through Innovative Adaptation, published by McGraw-Hill, and
The Baldrige: What It Is, How It's Won, and How To Use It To Improve Quality In Your Company.
Mr. Bogan has consulted on performance improvement and best practice competitiveness issues for a wide
range of pharmaceutical, biotechnology and medical device companies, including Pfizer, Eli Lilly,
GlaxoSmithKline, Genentech, J&J, Amylin, Sanofi-Aventis, AstraZeneca, Amgen, Novartis, Roche, Baxter
Healthcare, Bayer, 3M Pharmaceuticals, Abbott Laboratories, Astellas, LifeScan, Guidant, Janssen
Pharmaceutica and others.
Mr. Bogan led the consulting teams that assisted both Federal Express and GTE Directories (now Verizon) in
winning the prestigious Malcolm Baldrige National Quality Award. He has also advised many leading
corporations outside the healthcare sector, including industry leaders such as Microsoft, American Express,
AT&T, General Motors, BellSouth, Chevron, Exxon, Xerox, Verizon, Marriott, Merrill Lynch, Siemens,
KPMG, the New York Times Company, J.P. Morgan Chase & Co., TIAACREF, Nortel Networks, Pitney
Bowes, Bank of America, Wachovia and many others.
A guest lecturer at Northwestern University’s Kellogg School of Management and the University of North
Carolina’s (UNC) Kenan Flagler Business School, Mr. Bogan has spoken widely before business audiences in
North America, Europe, Asia and Latin America. He is an advisor to various management magazines on
best practice and management issues. He currently serves on the UNC Academic Leadership Institute’s
National Advisory Board. Previously, he served on the Board of Directors of Ontogeny, Inc., a stem cell and
functional genomics company now named Curis, Inc.
Prior to founding Best Practices, LLC, Mr. Bogan was a principal and founding member of The TQM Group,
Ltd., a Bostonbased consultancy. Mr. Bogan also spent many years working at various media companies,
including Times Mirror Corp., Knight-Ridder Inc., Howard Publications and Cowles Publishing Co. He has
contributed articles to many newspapers and magazines, including The Harvard Business Review, Time,
Pharmaceutical Executive, PharmaVoice, MedAd News, Planning Review, The Los Angeles Times, The
Boston Globe, The Miami Herald, The Chicago Tribune and The Philadelphia Inquirer. Through his work,
Mr. Bogan has toured manufacturing and service companies throughout the world.
|
|
|
|
Branimir Brankov, M.D., M.B.A.
Sr. Director, Strategic Business Intelligence
Merck & Co., Inc.
Global Competitive Intelligence Group (GCI), Whitehouse Station
Dr. Branimir Brankov is a professional manager and marketer with a medical and business background and
more than 15 years experience in the pharmaceutical industry.
Dr. Brankov is currently responsible for Strategic Business Intelligence Group which is part of the Global
Competitive Intelligence Unit established in the Merck Headquarter in Whitehouse Station, N.J., U.S.A. In
this capacity, his main functions include managing global projects and initiatives, conducting competitive
analysis and providing guidance to Merck Executives and Global Marketing Teams on strategy
development.
In his previous roles at Merck, Dr. Brankov has been Global Leader for Physician Communities of Practice
initiative at Merck. As part of the Global market research team in Merck Headquarter he has been
responsible for providing global market research and business intelligence support for several therapeutic
areas. Before his assignments in Merck Headquarter Dr. Brankov was responsible for establishing and
managing independent subsidiaries for Merck & Co., Inc. in Bulgaria, Macedonia and Albania.
Dr. Brankov received his M.D. from the Medical University of Sofia and practiced at the Military Medical
Academy in Sofia, Bulgaria, specializing in Neurosurgery. In 2001, he obtained a Masters’ Degree in
Economics from the Economics University of Sofia, with concentration in Human Resources; and, in 2003,
he earned a Masters’ Degree in Business Administration from Rutgers University, New Jersey, with
concentration in Marketing and Management. He is active member of PBIRG, SCIP and MRII.
|
|
|
|
Avis L. Bridgers
Analyst
Nerac
Nerac Analyst Avis L. Bridgers works closely with pharmaceutical and biotechnology companies to analyze
patent portfolios, identify complimentary intellectual property and licensing opportunities and to track new
technology and regulatory trends which are likely to impact their businesses. With more than 20 years of
experience as an innovative researcher, leader, and consultant in the pharmaceutical and biotech
industries, she has the expertise to identify opportunities and risks, to troubleshoot processes, and to avoid
the pitfalls of new ventures. Before joining Nerac, Ms. Bridgers founded a consultancy which helped
pharmaceutical and biotechnology companies optimize lead drug candidates early in the development
process. She has held leadership positions in biotechnology and contract research organizations. In her 15
years at Glaxo and Glaxo-Wellcome, Ms. Bridgers built her expertise in preclinical drug development, high
throughput absorption and metabolism screening and bioanalysis. Ms. Bridgers also developed in vitro
models of absorption to enhance the understanding of drug transporters, key differences in the various
routes of absorption and mechanisms of absorption enhancement.
Ms. Bridgers earned a master’s in organic chemistry from the University of North Carolina at Chapel Hill and
bachelor’s in chemistry at S.U.N.Y. Oneonta. Among her areas of expertise are preclinical drug
development, in vitro absorption models and assays, metabolite isolation and purification, transporters and
transport mechanisms, delivery of small molecule drugs and biologics, culture of immortalized cell lines,
cell-based assay methods, and bioanalytical methods development and instrumentation. She is a member
of the American Association of Pharmaceutical Scientists. She has published numerous articles in
scientific journals and is an ad hoc reviewer for Biochemical Pharmacology, Journal of Pharmaceutical
Sciences, and Journal of Pharmacology and Experimental Therapeutics.
|
|
|
|
Peter Burke
Senior VP & Chief Technology Officer
Steris Corp.
Dr. Peter A. Burke serves as Senior Vice President and Chief Technology Officer for STERIS Corporation.
He joined the Company in March 2001.
Dr. Burke is responsible for STERIS’s research, development, and regulatory functions. He works closely
with the Company’s marketing, sales, manufacturing, and support functions to facilitate new applications of
current technologies, leads the development of new technologies from conception to commercialization,
and monitors and assures compliance with applicable regulatory requirements for the Company’s products.
Dr. Burke also serves as a key member of the Executive Management team, and helps to assure that the
Company’s technological capabilities support and enhances STERIS’s growth objectives.
Dr. Burke holds a Bachelor of Science in Microbiology from Rutgers University; a Master of Science in
Microbiology from Seton Hall University; and Masters and Doctorate of Philosophy Degrees in
Microbiology/Biochemistry from St. John’s University. He also is a Fellow of the American Institute of
Chemists, a member of the New York Academy of Sciences, and a member of Sigma Xi. Dr Burke has
authored over 15 patents and 20 publications in chemical, microbiological, biochemical, and
dermatological sciences.
|
|
|
|
Jack Bush
Director, Global Pharmaceutical Market Intelligence
Alcon
Jack Bush joined Alcon Labs, Inc. as the Director of Global Pharmaceutical Market Intelligence in 2005.
Jack is a 20 year Marketing Intelligence professional. Previous to Alcon, he worked for Merck KGaA as their
Global Head of Business Research and Analysis. He held a global team dedicated to providing primary
research, secondary data analysis, competitive analysis, and forecasting. Prior to that position, he held
various global and domestic positions at Glaxo-Welcome, now known as GSK, Roche, formerly known as
Boehringer Mannheim and Merrill-Dow Pharmaceuticals. His career experiences also include Strategic
Planning, International Marketing, and New Business Evaluation. His experience spans across the
pharmaceutical and diagnostic industries.
Jack graduated from the University of Indianapolis in 1977 with a B.A. in Biochemistry. Jack also attended
Indiana University’s School of Medical Technology and received a B.S. in 1978 and is registered with the
American Society of Clinical Pathologists. In 1985, Jack received his Masters in Biology and Business
Administration from the University of Indianapolis.
As Director, Global Pharmaceutical Market Intelligence, Jack leads a global team with the responsibility for
primary market research, secondary market data analysis, competitive intelligence, forecasting and new
business/product assessments.
|
| |
|
Deborah Dauber
Associate Director, Competitive Intelligence
Genentech
Deborah Dauber has been with the Genentech Competitive Intelligence group for two and a half years.
She is currently serving as interim head of the CI group in addition to her primary responsibility as
immunology lead, supporting decision making for both R&D and Commercial immunology teams.
Deborah has led competitive intelligence initiatives to investigate key competitors (product and
company-level), evaluate revenue impact of competition, and assess full market landscapes. Prior to
joining Genentech, Deborah was a Consultant with WWMR, Inc., where she worked with clients to design
and execute market/opportunity assessments and managed the analyst team on custom projects.
She has a B.S. in Chemistry/Cellular and Molecular Biology from the University of Michigan, Ann Arbor,
and a Ph.D. in Chemistry and Chemical Biology from the University of California, San Francisco.
|
|
|
|
Tom Daulton
Vice President & General Manager
Cardinal Health
Tom Daulton is the Vice President and General Manager of Cardinal Health’s Global Interventional
Specialties and Medsystems Divisions, These divisions are dedicated to Interventional Radiology devices
used in Body, Spine Pain and Venus interventions And advanced Enternal Feeding products respectively.
Mr. Daulton has been in the medical industry for 20 years. Starting his career at IBM in their Medical
Software business and moving to Baxter Healthcare, Allegiance Healthcare and Cardinal Healthcare (all
through a series on company merges and divestures). Tom has held numerous senior leadership positions
in Marketing, Corporate M&A, Sales, and General Management – both domestic and internationally.
The majority of his career has been in manufacturing divisions ranging from Pharamseal Anesthesia and
Operating Room Division, Airlife Respiratory Care, Thermal Systems, Health Systems, Post Acute Care and
Special Procedures Radiology Division. Tom Has sat on numerous industries trade and association boards
including AORN (American Operating Room Nurses) NSCA (National Sub acute Care Association), AARC
(American Society of Respiratory Care), AvaMed (formerly HIDA/ HIMA) and the SIR Corporate Advisory
Board.
Tom has had considerable experience with in/out licensing, co development with physicians and
companies, and has led multiple acquisitions, licenses and divestures for Baxter, Allegiance and Cardinal
Health
Mr. Daulton earned a Bachelors of Science degree from Arizona State University in Tempe, AZ
Tom lives with his wife Jennifer, and three children in Racine, WI.
|
|
|
|
James Down
Vice President and Process Executive / Product Lifecycle Management
BD Diagnostics - Preanalytical Systems
|
| |
|
Michael DePeri
Director of US CI
Roche Laboratories
|
|
|
|
Joseph DeVivo
Global President, Reconstructive Orthopaedics
Smith & Nephew
Joseph DeVivo, 41, is president of the company's Orthopaedic Reconstruction & Trauma business unit.
DeVivo joined Smith & Nephew in June 2007. DeVivo has 18 years of marketing, development, sales,
operations and executive leadership experience, having most recently served as President and Chief
Executive Officer of RITA Medical Systems, Inc., a pioneer of radiofrequency ablation technology, which
was acquired by AngioDynamics in 2006. Previously, he served as President and Chief Operating Officer of
medical robotics company Computer Motion, Inc., where he helped turn the company’s performance
around ahead of its merger with Intuitive Surgery, Inc in 2003. From 1993 to 2002, DeVivo was at United
States Surgical (USS), a division of Tyco Healthcare, where he held a wide variety of roles, including Vice
President and General Manager of the USS/DG Sutures division, Senior Director of global marketing and
Director of Product Development. DeVivo holds a B.S. in Marketing and Management from the University
of Richmond, Richmond, Va.
|
|
|
|
Carolyn J. Foster
Sr. Associate Director, Technology Assessment
Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. Foster joined Boehringer Ingelheim Pharmaceuticals in 2001 and now heads the Competitive
Technical Intelligence group for cardiovascular and autoimmune diseases. In that capacity, she analyzes
the external environment in the context of internal business issues, especially where technology is a factor.
Her internal clients include R&D, Marketing and Medical management and the analysts that support them.
Prior to her CTI career, Dr Foster spent 20 years as a biochemical pharmacologist in Cardiovascular Drug
Discovery at Schering Plough working on drugs to treat hypertension, atherosclerosis, thrombosis, and
Parkinson’s Disease. Her published research focuses on G-protein coupled receptors and platelet function.
Dr. Foster studied chemistry at Swarthmore College, received an M.S. in biochemistry from Brown University
and a Ph.D. in pharmacology from the University of Medicine and Dentistry of New Jersey. She did post-
doctoral research at the University of Pennsylvania in human genetics. She is a Fellow of the New York
Academy of Sciences where she has served as a member the conference planning committee, as Chair of
the Biochemistry Section, and as head of the Biochemical Pharmacology Discussion Group, an academia-
industry consortium.
|
| |
|
Robert Franc
Director of Competitive Intelligence
Centocor
Robert Franc has over 26 years of Competitive Intelligence Experience; 12 years working for the US
Government and 14 years in the pharmaceutical industry. He has developed CI programs in the US,
Europe, Asia & the Middle East. During his 14 years in the pharmaceutical industry, he has supported R&D
and commercial organizations, both in the US & Europe.
Robert has spent the past 5 years as the Director for Competitive Intelligence for Centocor, a biotechnology
company in the Johnson & Johnson pharmaceutical business.
|
|
|
|
Sean D. Freston
Managing Director Asia/Pac
Proactive Worldwide
Sean Freston is the Managing Director, Asia-Pacific for Proactive Worldwide.
Sean has 15 years of experience living in and conducting business with China and the Asia-Pacific region.
Over the past three years he has been based in Shanghai tasked with business development in Asia for a
global CRO. In his previous role with Proactive Worldwide, Sean led the pharmaceuticals practice in
conducting domestic and international competitive intelligence engagements. Over the course of five
years, he was intimately involved with decision support projects across multiple therapeutic areas from early
discovery through marketing/lifecycle management initiatives.
He holds an MBA from Thunderbird School of Global Management, Arizona, and a BA from the University
of Puget Sound, Washington.
|
|
|
|
Monika Giese
Head of Global CI
Novartis Pharma AG
Monika Giese is currently the Head of Global Competitive Intelligence at Novartis Pharma at their strategic
HQ in Switzerland.
Before working at Novartis, Monika worked for GSK, Solvay, IMS International and F.Hoffmann – La Roche.
Her experience ranges from information management via market research and business analytics to a
variety of functions in competitive intelligence.
Monika is a biologist by training, and also holds certified degrees in pharmacology, Information Science,
Market Research and Competitive Intelligence.
She’s currently also a member of the Strategic Insights Leadership Forum.
|
| |
|
Erik Glitman
Managing Director
Fletcher/CSI, LLC
Erik Glitman is a founder and Managing Director of Fletcher/CSI and serves as the Director of Global
Operations, Research, and Strategy. As a founder of Fletcher/CSI, he has been active in the Competitive
Intelligence industry for over 15 years. He has worked with clients in areas such as automotive, electronics,
Healthcare, IT, kitchenware, machinery, pharmaceuticals, and Telco.
As an active part of the Fletcher/CSI consulting practice, Erik has extensive experience in working with
clients to help them gain competitive advantage in the marketplace through the integration of qualitative
and quantitative CI collected from global sources. Fletcher/CSI, headquartered in Williston, VT, has been
active in the international CI marketplace since its inception and operates with 22 affiliate offices
world-side. International clients use Fletcher/CSI consulting services to understand competitor positions
and develop strategies to increase profitability. A global leader in ethical CI, Fletcher/CSI has a history of
accurate and timely analysis on competitive situations while working with clients to develop effective
strategies in rapidly changing markets.
Erik holds a B.S. degree in Economics from the University of Vermont, a B.S. in Environmental Studies from
Johnson State College, and an M.S. in International Affairs from American University. He is active with
local charities and serves on the board of the Vermont Multiple Sclerosis Society Bike Tour, to be held in
August of each year.
|
|
|
|
Neil H. Gray
Managing Partner
Healthcare Trends & Strategies, LLC
Neil was previously Executive Vice President, Global Marketing and Strategy for Wolters Kluwer Health’s
Pharma Solutions division in Parsippany, NJ. There he was responsible for new product development,
brand management, advertising and promotion, public relations, market research, and competitive
intelligence. Neil also managed the organization’s editorial resource center (ADIS) in Auckland, NZ and its
IT functions. Prior to this, Neil was Senior Vice President, Strategy and Commercial Development, as well
as Senior Vice President, Marketing and Sales at Advanced Clinical Communications in Lambertville, NJ.
Before Advanced, Neil was Senior Vice President, and founding Managing Director of Torre Lazur
Managed Care from 1996-1999, responsible for provider communications and patient preparedness
programs, compliance and persistency projects, health risk assessments, patient education, wellness and
prevention initiatives, and advocacy group development. He joined Torre Lazur Healthcare Group in
August 1996 from Physicians World Communications Group in Secaucus, where he was Vice President,
Account Manager, and managed the company's education business in radiology and surgery. Prior to
Physicians World, he was Vice President, Management Supervisor at Health Learning Systems, a
CommonHealth USA company. Neil has over thirty years of industry experience, including time as Director
of Marketing for Livingston-based Saint Barnabas Medical Center, New Jersey's largest acute care hospital.
Neil also has worked for Medical Economics, McGraw-Hill, CBS/Holt Rinehart Winston, and John Wiley &
Sons publishers.
Therapeutic areas of experience include anti-infectives, biologicals, cardiovascular, critical care,
endocrine, female healthcare, gastroenterology, hospital marketing, managed care marketing, medical
devices, nutritionals, nursing, oncology, OTC products, pharmacy, primary care, radiology, surgery, and anti-
virals.
A frequent speaker and conference leader at industry meetings, his strategic interests focus on advocacy,
new product development, global market and life cycle planning, war gaming and competitive scenarios,
and medical science liaisons’ (MSL) differentiation and competition via leadership, value, thought leader
development, and problem solving.
|
| |
|
Thomas Han
Director, Strategic Marketing
Biovail
Mr. Han has over sixteen years of successful pharmaceutical industry experience including in-depth
experience within strategic marketing, pre-launch commercialization, product launches, brand marketing
and field sales.
Mr. Han started his pharmaceutical career in field sales and was successfully promoted to positions within
sales operations and marketing at Bristol-Myers Squibb. He then moved into marketing roles at both
Novartis and Schering-Plough. Mr. Han has had the opportunity to hold leadership roles on both small and
blockbuster brands.
In his current role, he is responsible for leading the product candidate identification and commercial
assessment process for Biovail. This includes forecast development and market research to validate and
quantify the risks associated with each opportunity across multiple therapeutic areas.
|
| |
|
Peter Hegi (invited)
Director of Marketing, Programming and System Integration
ANA A St. Jude Medical Company
|
| |
|
Christian Hein
Business Intelligence Director
Actelion Pharmaceuticals Ltd
Christian Hein has been working with Actelion Pharmaceuticals for 2 years, building up the Business
Intelligence and Market Research department from scratch. Actelion, headquartered near Basel,
Switzerland, is one of the leading biopharmaceuticals worldwide. Founded in 1997, the company now has
3 products on the market, and has generated 2007 revenues of over CHF 1.3 bn. At Actelion, Christian is
responsible for all global competitive intelligence and market research activities, focussing on more than
16 indications for both in-line and development products.
Before joining Actelion, Christian has been working as a strategy consultant and venture capital investor for
the biopharmaceutical industry. Christian holds advanced degrees in biotechnology and molecular biology
from Strasbourg University and a Master's degree in Strategic Management from HEC Business School in
Paris.
|
| |
|
Richard Hendriks, Ph.D.
Analyst
Nerac
Nerac Analyst Richard Hendriks, Ph.D., partners with pharmaceutical companies to discover the most recent
clinical trials for new agonist or antagonist compounds, and analyzes prior art in the field of drug
combinations to treat certain conditions. His work centers on drug actions, neuroscience, and human and
animal studies. Dr. Hendriks also has researched such topics as “Nitric Oxide in Combination with NSAIDs to
treat Muscular Dystrophies,” and “Therapeutic Applications of Alpha-1 Adrenergic Agonists.” He has a Ph.D
in neuroscience from University of Melbourne, Australia, and a background in the area of electrophysiology.
Dr. Hendriks has received several grants and fellowships from the National Institutes of Health and the
National Science Foundation. He has been a principal investigator for various studies. Dr. Hendriks’ early
research focused on neuronal receptor pharmacology, including a compound that was commercialized as
Tropisetron. His subsequent research moved to the subject of the central nervous system and included an
investigation into the role of potassium channels in embryonic neuronal migration as part of an
investigation into potential cures for deafness. Dr. Hendriks has authored dozens of published articles and
abstracts on such topics as physiology and electrophysiology. Besides neuroscience and electrophysiology,
Dr. Hendriks’ areas of expertise include neurophysiology, pharmacology, receptors & ion channels,
biophysics, developmental neuroscience, drug development, electrophysiology, bioengineering and
neurotransmitters.
|
| |
|
Dave Hitchcoff
Vice President Consulting Services
Dunn Group
David Hitchcoff is Vice President of Consulting Services at The Dunn Group, Inc (TDG). David also serves
as Global Team Leader on selected competitive intelligence projects. He has been with TDG for over
eight years and has managed over 50 projects. One of his global teams simultaneously deployed ten
primary Research Analysts, a Medical Director and Pharmacology Advisor.
David has developed numerous project management tools and techniques to synchronize intelligence
research and information development with information requirements (Key Intelligence Topics) these
processes have been presented at professional development seminars such as the N.J. Society of
Competitive Intelligence Professionals Education Day. He has also attended over 100 medical
conferences and has drawn upon this experience to develop the methodology presented at the Fourth
Annual Pharma & Biotech Business Intelligence Summit and the 2005 Pharmaceutical Business
Intelligence Research Group Annual General Meeting in 2004.
David worked closely with outside counsel to develop the TDG C.I. Collection Guidelines and has
informally advised numerous clients in this area in addition to authoring an article on the subject for
Regulatory Affairs Focus the Journal of the Regulatory Affairs Professional Society.
Prior to joining TDG, David held numerous executive positions during twenty-five years in the medical
device and instrumentation sector including:
- V.P. Sales and Marketing at Colin Medical Instruments (CMI)
- Director of Regulatory Affairs at CMI
- Director of Cardiovascular Instrumentation at Gould Corporation
- Director of Marketing at Datascope Corp.
A native of New Jersey, David’s various assignments have taken him to Southern California, Northern
California and Texas. He and his family currently reside in Montville, New Jersey.
|
|
|
|
Gerald (Jerry) Hoffmann
Manager-Global Competitive Intelligence Strategy
Eli Lilly
Jerry Hoffmann has been actively involved in competitive intelligence since 1989. In that year, after a
variety of positions with SBC Communications*, he was called upon to establish the company’s first
corporate-level CI organization. From that time until his retirement in 1998, Jerry led SBC’s competitive
intelligence function through a period of enormous change, both in the telecommunications industry and
within his company. At the time of his retirement, he was director of all of SBC’s competitive intelligence
operations throughout the United States.
In 1998, Jerry joined Eli Lilly and Company as an advisor to the director of the company’s newly formed
corporate competitive analysis function. What began as a limited engagement has since become a new
career. Jerry manages the implementation of Lilly’s CI processes, designs and conducts CI projects and
continues to serve as advisor, teacher and coach to those who want to develop – or simply use – quality
competitive intelligence. He has also assumed the leadership of Lilly’s Global Competitive Intelligence
group.
Jerry has been a member of the Society of Competitive Intelligence Professionals since 1989 and was a
charter member of the Conference Board’s Council on Competitive Analysis while at SBC. He has since
rejoined this panel of advanced practitioners, now representing Eli Lilly and Company.
|
| |
|
Coralie Hughes
Manager, Global Competitive Intelligence
Eli Lilly
|
| |
|
Dr. John Jakupciak, PhD
Director, Biomedical Research
Cipher Systems
|
|
|
|
Cliff Kalb
President
C. Kalb & Associates
Clifford Kalb currently serves as Vice President, Life Sciences at Wood Mackenzie, Inc.
In this capacity he provides thought leadership on industry issues and supports their knowledge based
research and consulting practice.
Mr. Kalb has over thirty five years of experience in the pharmaceutical industry. Previously, he served as
Senior Director, Strategic Business Analysis, in Worldwide Human Health Marketing at Merck & Co., Inc.
Prior to that, he held positions of increasing responsibility in sales, market research, health economics,
public policy management, marketing management, licensing, business intelligence and business
development at Marion Labs, Pfizer and Roche. He has also served as head of marketing and business
development for a small biotechnology company.
Mr. Kalb has served as Chairman of the Conference Board Council on Competitive Analysis. He is also Past
President of the board of directors of the Society of Competitive Intelligence Professionals (SCIP), and Past
President of the Pharmaceutical Business Intelligence and Research Group (PBIRG). Mr. Kalb is widely
published in the field of pharmaceutical industry intelligence and analysis.
In 2004, he was made a Fellow in SCIP, and received the Lifetime Achievement Award from PBIRG. In
2005, he was named one of top 100 most inspiring people in the pharmaceutical industry by Pharmavoice
magazine. Mr. Kalb holds a Bachelor’s degree in Biology and Psychology from Rutgers University, and an
MBA in Pharmaceutical Marketing and Economics from Fairleigh Dickinson University.
|
| |
|
Eileen M. Kelly
Director of Business Decision and Analyst
OSI Pharmaceuticals
Eileen Kelly has over twenty years of experience in the healthcare and pharmaceutical/ biotech industries,
primarily in the market research, business analysis, and business development fields. Eileen is currently the
Director of Business Decision and Analysis at OSI Pharmaceuticals, based in New York. She has previously
worked at Bristol Myers Squibb, Sanofi-Aventis, and Purdue Pharma in various commercial capacities,
primarily in the therapeutic area of oncology. Eileen also worked for over five years at Memorial Sloan
Kettering Cancer Center as a clinical oncology nurse.
Eileen completed her Ph.D. and undergraduate work in Social Psychology at the State University of New
York at Stony Brook and she received her Bachelor’s of Science in Nursing from Columbia University.
|
|
|
|
Dick Klavans
President
SciTech Strategies, Inc.
I have been a consultant since 1978. My clients have included large R&D intensive firms (Abbott Labs,
Astra Zeneca, Dupont, Glaxo, Kellogg, Kraft, SmithKline Beecham and Unilever). I provide accurate maps
of the scientific and technological environment based on a proprietary technology (described in the
literature below). One of my maps of science was selected as the highlight of a six month exhibit at the
science & industry branch of the New York Public Library; was archived in their permanent map collection
and was subsequently published in Nature [Dec 12/28, 2006 p.985]. My most recent contract with the
University of California at San Diego focused on a major improvement in the methodology for visualizing
the structure of academic scholarship in order to better understand the relationship between the natural
science, social sciences and the humanities.
My primary professional association is with SCIP (The Society of Competitive Intelligence Professionals). I
was elected to the SCIP Board of Directors (1993-1996) and served as President in 1994. In 1999, I
received their Meritorious Award- the highest award for achievement in and contributions to the field of
competitive intelligence (only 11 Meritorious awards had been given out over the 15 year history of this
5000 person association).
|
| |
|
Susanne Laningham
Director, Business Analysis & Information
Amgen, Inc
As a Director of Business Analysis & Information, Susanne Laningham leads the Competitive Intelligence
team. The group supports both in-line and pipeline products at Amgen by providing business insights that
facilitate the proactive development and execution of product and corporate strategies.
Prior to joining Amgen, Susanne was a Senior Practice Executive at Campbell Alliance, specializing in the
development of reimbursement strategies for products in highly competitive markets. While at Campbell,
she also helped product teams develop lifecycle management strategies to maximize the value of key
therapeutic franchises.
Susanne has an undergraduate degree in chemistry from Duke University, a masters in chemistry from the
University of Virginia, and an MBA from the University of North Carolina at Chapel Hill.
|
|
|
|
Steve Levy
Managing Director
Fletcher/CSI, LLC
Steven heads up the Competitive Intelligence Integration Practice for Fletcher/CSI’s Pharmaceutical Sales
and Marketing Practice and has worked extensively with both pharmaceutical, biotech and healthcare
organizations in the design and implementation of Competitive Intelligence programs and processes into
their detailing, marketing, and physician/patient awareness programs. Steven has a 20-year back ground in
managing global direct and indirect driven marketing and sales channel networks and is actively involved
in the formulation, and on-going design of Fletcher/CSI’s marketing and sales healthcare research
practice. He is a global speaker and workshop instructor on the subject of sales force effectiveness and is a
recognized international speaker on pharmaceutical sales effectiveness. He is an active member of the
Society of Competitive Intelligence Professionals, and has been the Chair of the Society’s Sales &
Marketing Intelligence Symposium. Steve is an originator of the Pharmaceutical Business Intelligence
Summit and the Clinical Trial Registries Symposium.
|
|
|
|
Mark Little
Vice President, Business Intelligence
Covance, Inc.
Mark is currently Vice President, Business Intelligence at Covance Inc. in Princeton NJ. Mark joined
Covance in 2002, and has since merged the intelligence function with the market research function to form
a more comprehensive, external-focusing unit at Covance. Before joining Covance, Mark worked in the
pharmaceutical industry with Glaxo, where he led a business-driven competitor intelligence operation that
effected decisions related to both R&D and commercial strategies.
Mark received a BS in chemistry from the University of North Carolina and a Ph.D. in biochemistry from The
Ohio State University. Following his doctorate, Mark received a National Science Foundation fellowship to
conduct research at the University of Grenoble, in France.
Mark has been active with the Society of Competitive Intelligence (CI) Professionals, or SCIP, the
5000-membered organization for CI. Mark served as SCIP President in 2001-2002, and as a Board member,
1998-2003, and is currently a member of the SCIP Education Committee. Mark is also a member of the
Intelligence Leadership Forum, a thought-leading intelligence organization established in 2003.
Mark has given frequent presentations on CI at conferences and business schools, and has authored several
articles on the subject.
|
|
|
|
John J. Mahoney
Co-Founder, CTO
InfoNgen
John J Mahoney is co-founder and CTO of InfoNgen, where he is the architect of the firm's overall product
and technology strategy. Previously John was a founder and CTO of Multex.com, where he navigated the
company through its transition to the internet, and the subsequent rapid expansion of its product portfolio.
An avid blogger, John posts frequently about various topics, mostly technology focused, on his personal
blog The Digital Edge (www.thedigitaledgeblog.com).
|
|
|
|
Martha Matteo
Former President, SCIP, and
Former Director, Knowledge Management & R&D Planning
Boehringer Ingelheim
Dr. Matteo has been a Board Member of the Society of Competitive Intelligence Professionals (SCIP) since
2005 and was President in 2007. She received the Society’s Catalyst Award in 2006 and has co-chaired
two meetings for SCIP on the subject of Competitive Technical Intelligence (CTI). She has spoken widely
on this subject at SCIP and other meetings. Recently retired after 25 years at Boehringer Ingelheim
Pharmaceuticals, Inc, Dr. Matteo has been involved with CTI since 1988, when she founded the company’s
CTI function. Dr. Matteo has also been active in the New York Academy of Sciences, where she chaired the
Biochemistry Section and the Biochemical Pharmacology Discussion Group. She is a Fellow of the
Academy and served on its Board. Dr. Matteo has a PhD in biochemistry from Brandeis University and was
a founding faculty member of the University of Massachusetts/Boston. After an academic career, she
transitioned to applied research in industry, first at Union Carbide and then at Boehringer Ingelheim. Dr.
Matteo remains active in SCIP and the field of CTI.
|
|
|
|
Graig McHenry
Senior Director, Competitor Insights
Wyeth
Craig joined Wyeth (formerly American Home Products Corporation) in 1991 and advanced his
understanding of the pharmaceutical industry while working in several business functions. He started in
Global Business Development and Licensing before moving to manage the Secondary Research Analysis
function. He has also worked in Marketing Research where he spent two years directing oncology and
hematology market research in the Wyeth BioPharma business unit. Since early in his career at Wyeth,
Craig has been involved with competitive intelligence. In 1993, Craig played a key role in forming the first
Business and Competitive Intelligence function, which has evolved over the years into the current group
that he directs called Competitor Insights. One of a handful of groups focused on specific analysis
techniques, this group provides CI consulting, expertise, and oversight to brand teams, new product groups,
and Senior Management. Before Wyeth, Craig spent five years at Unisys and holds a M.A. in Computer
Science Ed. He has been a member of SCIP since 1993 and is a graduate from the Gilead-Herring
Academy of Competitive Intelligence.
|
| |
|
Gary McKnight, Ph.D.
Director of Information and Competitive Intelligence
ZymoGenetics
Gary is currently Director of Information Services and Competitive Intelligence at ZymoGenetics in Seattle ,
Washington , USA , at which he has been employed for over 24 years. His Ph.D. work involved yeast
genetics and molecular biology from The University of Rochester with postdoctoral work at The University of
Washington. Gary 's current work as a CI practitioner involves reviewing emerging literature and news that
have relevance to the company’s pipeline. He is a primary contributor to the evolving cross-functional CI
and Analytics team at ZymoGenetics and directs the staff in Information Services.
|
|
|
|
Holger Meissner
Co-Founder and President
Adler Life Sciences
With over 20 years of experience in the Self-Medication market, as well as work experience in eight
countries in local, regional and global positions, Holger brings unique and well-seasoned in-company
perspectives to Adler Life Sciences.
Prior to founding Adler Life Sciences, Holger was the Head of the Global Competitive Intelligence at Bayer
HealthCare Consumer Care Division in Morristown, New Jersey. He joined the Bayer Group in 1985.
Throughout his years at Bayer, he held positions of increasing responsibility in local, regional and global
marketing functions for the Consumer Care Division, managing brands such as Bayer Aspirin, Alka-Seltzer,
Canesten, Talcid and Bayer’s former Household Brands such as Baygon. During this time he worked in
various countries such as Germany, Colombia, South Korea, Japan, Hong Kong and China. In 2002, Holger
moved to Morristown, New Jersey, the location of the global headquarters of Bayer HealthCare Consumer
Care Division.
He was born in 1965 in Aachen, Germany and received his degree as “Wirtschaftsassistent” in 1988. He is
married and has one child.
|
|
|
|
Rajesh Nair
CEO
Indegene
Dr. Rajesh Nair is the President and CEO of Indegene worldwide group of companies, the leader in global
pharmaceutical knowledge services.
Since 1998, Indegene has been a pioneer in knowledge services with a global presence that includes 11
offices across 4 continents. With an in-house team of more than 250 fulltime employees including more
than 125 MDs, PhDs and PharmDs providing profound domain expertise, Indegene’s unique hybrid global
delivery model helps clients gain the benefits of cost efficiency, scalability and reliability. Indegene is an
ISO 9001/27001 certified organization and works with the leading pharmaceutical and biotechnology
organizations worldwide.
Rajesh has been a part of Indegene growth over the past 10 years and has worked extensively in the Asian
and US markets with global as well as regional companies. His areas of focus and interest include
globalization of skilled knowledge services, innovation models, and the emerging next generation
pharmaceutical and healthcare paradigm.
Rajesh received his medical degree from India and was a practicing clinician before being accepted for
the prestigious MBA program at the Indian Institute of Management, Ahmedabad. Dr. Nair has worked in the
pharmaceutical industry focusing on biotech licensing and clinical trial activities leveraging the US-Asia
corridor.
Dr. Nair is based out of Princeton, NJ.
|
|
|
|
Marjorie Norman
Manager, Information & Knowledge Management
Pfizer Global Research & Development
Ms. Norman has over eighteen years’ experience in business and competitive intelligence, as well as market
research in corporate, consulting and entrepreneurial environments. Her focus has been in the
pharmaceutical and medical device industries.
As a Manager in the Competitive Intelligence Center of Excellence at Pfizer, Inc., Ms. Norman provides
strategic business intelligence to senior R&D and commercial management.
Prior to joining Pfizer, Ms. Norman was Director – Pharmaceutical Practice, at Fuld & Company, a
competitive intelligence consulting firm, where she managed and researched numerous projects in the
pharmaceutical, medical device and healthcare sector. Sample projects included determining product
characteristics for a novel diagnostic device, conducting numerous timing studies for new product
launches, and tracking strategic alliances. Ms. Norman is also experienced in conducting elicitation,
conference quarterbacking and war-gaming training sessions.
Ms. Norman began her career with Johnson & Johnson Professional, Inc., as a Senior Market Research
Analyst for where she evaluated new business opportunities and performed market assessments through
primary and secondary research. She has extensive experience working directly with physicians,
moderating focus groups and performing in-depth one-on-one interviews.
Ms. Norman holds a Master of Business Administration degree from the Graduate School of Management at
Simmons College in Boston, Massachusetts and a Bachelor of Arts degree in German and Art History from
Franklin & Marshall College in Lancaster, Pennsylvania.
|
|
|
|
James (JJ) Owen, Ph.D.
Associate Director, Scientific & Competitor Analysis
Millennium Pharmaceuticals
With over 6 years of experience in the competitive intelligence field, JJ is an Associate Director leading the
Scientific & Competitive Analysis group at Millennium Pharmaceuticals in Cambridge , MA . The group’s
responsibilities include the monitoring of competition from R&D through Commercial and working on cross-
functional initiatives within the company.
Previously, JJ spent several years as an analyst within Business Development at AVEO Pharmaceuticals
assisting with market research, public relations, licensing partnerships and R&D collaborations. Other work
experience include a stint with a Knowledge Management function at Millennium Pharmaceuticals and
managing teams of curators/editors while at Proteome/Incyte Genomics.
JJ holds a B.S in Microbiology from Mississippi State University and a Ph.D. in Cell Biology from Vanderbilt
University .
|
|
|
|
Joshua Owolabi
Assistant Director, Discovery & Assessment Group
TAP
Joshua B. Owolabi, Ph.D., MBA, is Assistant Director, Technical Assessment, TAP Pharmaceutical
Products, Inc. In this capacity, Dr. Owolabi reports to the Vice President, Scientific Affairs of TAP, and is
responsible for the technical assessment management systems, which include competitive technical
intelligence, disease condition assessment, opportunity flow management, scientific evaluation and due
diligence of new technologies and product opportunities in support of TAP’s gastroenterology, urology,
women’s health and metabolic diseases franchises.
Before joining TAP, he was Manager, Discovery Biology at Allelix Biopharmaceuticals Inc., Canada
(currently known as NPS Pharmaceuticals, Inc.).
Dr. Owolabi holds a Ph.D. in Microbiology from the University of British Columbia, and an MBA from the
North Park University.
|
|
|
|
Daniel Pascheles
Vice President, Global Competitive Intelligence
Merck
Dr. Daniel R. Pascheles is Vice President, Global Competitive Intelligence, and is based in Whitehouse
Station NJ, at the Global HQ of Merck & Co., Inc.
His responsibilities include providing intelligence regarding business, research and development activities
of competitors, as well as participating in, and contribution to the strategy development process, the target
identification for licensing and M&A activities.
Pascheles joined Merck & Co., Inc. early 2005 from Aventis Inc. where he was Vice President and head of
Corporate Competitive Intelligence. He has worked for Aventis and its predecessor company (Hoechst
Marion Roussel, Marion Merrell Dow) for 14 years in various positions and locations.
Pascheles studied Pharmacy at the Swiss Federal Institute of Technology in Zurich, Switzerland. He
received his Ph.D. in Pharmaceutical Technology from the same university. He has done additional study
at the University of Kansas in Lawrence, Kansas.
Pascheles is Past-President and current Board member of the Pharmaceutical Business Intelligence &
Research Group (PBIRG). He is also member of the Society of Competitive Intelligence Professionals
(SCIP) and the Licensing Executive Society (LES).
|
| |
|
Hari Patel
Associate Director of Business Intelligence
Bayer HealthCare
|
|
|
|
Jonas Pedersen
Executive Director
Deallus
Jonas Pedersén is Partner and Executive Director at Compelling Edge LLP with responsibilities for the
company’s CI consulting and wargaming operations. In this capacity Jonas has supported several top 10
Pharmaceutical and Biotechnology companies in establishing and training their CI functions and
conducting strategic exercises ranging from Scenario Learning to Wargaming. Jonas is also one of the
Founders of Compelling Edge CI Management School, the only such school exclusively focused on the
Life Science sector.
Jonas joined Compelling Edge from Amgen Inc, where he was the Director and Head of Competitive
Intelligence. At Amgen he built and developed a world class CI capacity that supported the
commercialization process and all branded assets across Amgen regions and functions as well as the
Senior Management. Previously, Jonas worked as Competitive Intelligence Manager for Therapy Area Pain
Control within AstraZeneca R&D. Prior to joining the CI profession, Jonas was an Assistant Professor and
acting Deputy Director at the Department of Musculoskeletal Research, National Institute for Working Life in
Sweden.
Jonas holds a PhD in Neurophysiology and a BSc in Psychology as well as an Executive MBA in General
Management.
|
|
|
|
Jeanne Penn
Director, Business Information, LSD Business
Genzyme
Jeanne is currently Associate Director of competitive and industry intelligence at Genzyme Corporation.
Her role includes providing competitive intelligence to product teams, identifying key industry trends and
their implications for Genzyme, and managing market forecasting for Genzyme’s Rare Genetic Diseases
business.
Before joining Genzyme in 2003, Jeanne spent more than a decade at Decision Resources, where she
worked on in-depth analyses across a wide range of indications including diabetes, osteoporosis,
osteoarthritis, and asthma. Prior to that, she worked for a number of other consulting firms, including Boston
Biomedical Associates and Bain & Co.
|
|
|
|
Renee Pierson
Director of Global Business Intelligence
Johnson & Johnson Pharmaceutical Services
Renee Pierson was recently appointed as Global Intelligence Leader, internal medicine & virology at
Johnson & Johnson Pharmaceutical Services. Prior to this appointment, she was Director of Business
Intelligence for Ortho-McNeil Janssen Pharmaceutical Services.
She joined the Johnson & Johnson Family of Companies in 1996 as a Manager, Marketing Research for
New Products at Ortho-McNeil Pharmaceutical and has since moved to positions of increasing
responsibility within the pharmaceutical sector at Johnson & Johnson. Prior to her appointment to Business
Intelligence, she held the position of Group Director, Marketing Research & Forecasting.
Renee has over 20 years of experience in the Pharmaceutical Industry. In addition to Johnson & Johnson,
she held positions at Novartis and Sanofi Aventis in areas of Finance, Business Planning and Market
Research. She is past President and Board Member of the Pharmaceutical Marketing Research Group
(PMRG) and has served on the Editorial Board for the Journal of Pharmaceutical Marketing & Management.
Renee is also a member of the Society of Competitive Intelligence Professionals (SCIP).
|
|
|
|
Rafaat Rahmani
President
Lifescience Dynamics Ltd
A highly experienced General management professional with specialist know-how in the areas of Strategy,
Marketing, Market Research, Competitive Intelligence, Pricing & Reimbursements, and Finance; spanning
over 25 years experience; 15 years in pharmaceuticals and biotechnologies industries; with both client and
consulting side experiences such as various marketing roles in industry and on professional services
developing and growing Market Research/Consulting.
He was Vice President of Double Helix Development, working on many varied life science and healthcare
consultancy assignments over a seven year period. Previously he worked for Eli Lilly in Finance, MR CI,
Portfolio, Marketing, CNS Business Unit and Strategy roles. In addition, he has a strong background in
FMCG marketing with Pepsi-Cola and General Management in UAE.
He has an MBA from Manchester Business School, UK and a BBA from the University of Houston, USA. He
has helped organisations with a variety strategic and operational issue. He has been married for 16years
and is a proud father of 3 children 2 girls and a boy.
He is passionate about harnessing and bringing to the market new products / technologies for the benefits of
mankind.
|
|
|
|
Chandra Ramanathan
Director, Global Business and Competitive Intelligence
Bristol-Myers Squibb
Dr. Chandra Ramanathan has been associated with pharmacy academia and pharmaceutical industry for
more than 22 years. He has successfully applied scientific insights to address business issues in oncology,
immunology, Neuroscience and gastroenterology. He has extensive experience in Identifying new
licensing/business development opportunities and conducting scientific and commercial due diligence on
both compounds and technology deals. He has played a key role at Bristol-Myers Squibb in providing
scientific and commercial insights for strategic decision making and has contributed to oncology,
neuroscience and immunology portfolio planning.
Dr. Ramanathan has contributed to the launch of Orencia (Biologic; Rheumatoid arthritis) and Sprycel
(small molecule; Chronic Myelogenous Leukemia) by incorporating competitive insights in marketing
strategy development and execution. He has worked across the product development and
commercialization spectrum from discovery, clinical development to marketing. He has successfully worked
in new product planning/product commercialization and has contributed to the development of clinical
and commercial strategy for early and late-stage compounds. He also played a key role in evaluating
biosimilars for potential opportunities and assessing risk for the commercial franchise.
|
|
|
|
Arun Ranchod
Business Development Manager
MEDRAD Corporate Innovations
Arun Ranchod is the Business Development and Advanced Marketing Manager at MEDRAD, a radiology
device manufacturer in western Pennsylvania. Mr. Ranchod has been with MEDRAD for 6 years and in the
healthcare technology marketing area for 14 years. He leads Corporate Strategic Planning efforts at
MEDRAD and has done so for the last 3 years. His current responsibilities include: leading Corporate
Strategic Planning efforts, working with MEDRAD’s European businesses to identify and develop potential
business growth vehicles, working with the CT business unit to identify and develop business growth vehicles
and investigating new business initiatives from a strategic marketing and Voice of Customer perspective. Mr.
Ranchod earned a Bachelor of Arts degree in Mathematics from the College of Wooster, a Master of
Science in Biomedical Engineering from the University of Virginia and a Master of Business Administration
from Syracuse University. He spent approximately 7 years as a Product Manager in the field of
pharmaceutical robotics and has worked in academic technology transfer, healthcare strategic marketing
consulting and venture capital. His interest in competitive intelligence stems from his need to learn about
niche markets prior to providing recommendations on various business initiatives.
|
| |
|
Sam Rosenbaum
Manager, Market Research
Philips Medical Systems
Sam Rosenbaum has been with the Philips Healthcare for two years. He is currently serving as Manager of
Global Market Research in the Ultrasound Division supporting new product introductions along with strategy
and business development.
Sam has led competitive intelligence initiatives to investigate key geographic and clinical market
landscapes and led core teams in development of new products strategies utilizing the Value Proposition
House process. Prior to joining Philips Healthcare, Sam was a Senior Market Research Analyst with Bristol-
Myers Squibb – Medical Imaging, where he supported marketing and business development with
competitive intelligence and market research.
He has a B.A. in Economics and Political Science from the Hobart College and is pursuing his MBA from
Babson College.
|
| |
|
Wayne Rosenkrans
Distinguished Fellow, MIT Center for Biomedical Innovation
Chairman & President, Personalized Medicine Coalition
Chief Applications Officer, SciTech Strategies
Wayne is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare
strategy and policy issues related to science and medicine.&n bsp; He is also Chairman, President and a
member of the board of directors of the Personalized Medicine Coalition, a Washington DC based
organization working with government and other agencies on evolving healthcare policy for Personalized
Healthcare, and Chief Applications Officer for SciTech Strategies focusing on scientific competency and
capacity development for academia and industry. He is a former Director of External Relations for the
Personalized Healthcare Team and Evidence-based Medicine (EBM) as part of External Medical Relations
at AstraZeneca where he had responsibility for long-range external relations strategy and policy
development. He is active on several strategy and advisory boards at different organizations including the
C-Path Institute, Georgetown University, IBM, HP, and the Personalized Healthcare Initiative in the
Secretary’s office at Health and Human Services. He has presented at numerous forums on aspects of
personalized healthcare, evidence-based medicine, new development paradigms, and strategy
development. He holds an S.B. in Biology from MIT, a Ph.D. in Cell and Molecular Biology from Boston
Univ., and received post-doctoral training in Cancer and Radiation Biology at the Univ. of Rocheste r.
Wayne lives in Malvern, PA, is married with two college-age children, and enjoys teaching martial arts
(Tang Soo Do), restoring antique/classic Fords, and aviation history.
|
| |
|
Bill Sammon
Senior Director of Strategy Information Analysis
Pfizer
Bill Sammon is Sr. Director, Strategic Information and Analysis, World Wide Investor Development and
Strategy at Pfizer Inc, New York City, NY. His responsibilities include: 1) supervising financial analyses and
industry studies assessing competitive threats and strategic opportunities in Pfizer’s business environment, 2)
providing strategic business intelligence to senior executives, and 3) leading the Corporate Business
Intelligence Advisory Group BIAG which advises business units and product management teams in the
development and management of their internal and external business intelligence resources. The Corp.
BIAG manages Pfizer’s relationship with all consultants contracted for primary business intelligence (BI)
projects at the Company.
Mr. Sammon earned a BA in political science from Boston College, an MA in political science from the
University of Chicago and an MBA from Long Island University. He’s worked at Pfizer since 1982 in various
planning and policy positions at both the corporate and operating group level (Corporate Affairs, Corporate
Strategic Planning, US Pharmaceuticals, and Investor Relations). He’s also held managerial and staff
positions in the military, academia and the investment community.
Following a decade of service in the Regular Army in infantry and military intelligence assignments in
Vietnam, Washington, DC, the Pentagon and the US Military Academy at West Point, New York, Bill
transferred to the US Army Reserve retiring as a Lieutenant Colonel in 1996. He’s a graduate of the Army’s
Military Intelligence Schools and the Command and General Staff College. From 1979 to 1982, he worked
at International Paper, New York City in Corporate Communications and Corporate Planning. He helped
International Paper establish its first industry/competitive analysis function. Bill also worked on Wall Street
as a sell-side stock analyst following the pharmaceutical industry from 1987 to 1990.
He is the editor and author of an early professional book on competitor analysis, Business Competitive
Intelligence, (John Wiley & Sons, 1984) and contributing author of a chapter on strategic business
intelligence to the Handbook of Strategic Planning, (John Wiley & Sons, 1986). Bill is active in the Society
of Competitive Intelligence Professionals (SCIP) and frequently presents on the role of business intelligence
in executive decision-making and strategic planning.
|
| |
|
Indra Sethy-Coraci
Principal Analyst, Competitive Technical Intelligence
Boehringer Ingelheim
Indra Sethy-Coraci joined Boehringer Ingelheim Pharmaceuticals in 2004 after completing her
postdoctoral studies at Columbia University and is now a Principal Analyst in the Competitive Technical
Intelligence group supporting autoimmune diseases/immunology. Prior to graduate school, her other
industry experience includes approximately five years at Genentech in the departments of Manufacturing,
Process Development Sciences and Cardiovascular Research.
Dr. Sethy-Coraci received a B.S. in Chemical Engineering at the University of California, Davis, a PhD in
Biochemistry at the Albert Einstein College of Medicine and completed her postdoctoral training in the
laboratory of Dr. Samuel C. Silverstein in the department of Physiology and BioPhysics at Columbia
University. Her postdoctoral research focused on understanding the role of mononuclear phagocytes in
inflammation in Alzheimer’s disease and atheroscleros |
|
